Dr. Shaywitz trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard. He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group’s Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco. He recently wrote Tech Tonics: Can Passionate Entreprenuers Heal Healthcare With Technology?
Ph.D., Biology, M.I.T.
M.D., Health Sciences & Technology Program, Harvard Medical School/M.I.T.
A.B., summa cum laude, Biochemistry, Harvard College
Since the majority of healthcare costs are attributable to a tiny fraction of patients—patients who are often the most complex, and who may not suffer from a single condition—you could argue that the key to controlling costs is to focus on the exceptions, rather than deprioritize them.
In investing, comedy, and business, timing is a key component of success. It’s not enough to have a sense of where the future is going, directionally – you have to have some sense of when it’s likely to arrive.
In Tech Tonics—a distillation of our writing and thinking over the last several years—we introduce the reader to the fascinating digital health space, including a ground-level view of the landscape, the structural challenges, the players, and the progress.
The basic challenge faced by medical products companies is that they’re trying to sell expensive products into an environment that’s increasing concerned about the cost of care, and in which key stakeholders are aggressively looking for opportunities to bring the costs down, and avoid unnecessary expenditures.